Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overview of stability study designs.

Tsae-Yun Daphne Lin1, Chi Wan Chen

  • 1Office of Biostatistics, Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20850, USA. Lind@cder.fda.gov

Journal of Biopharmaceutical Statistics
|August 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical drug classification.

International journal of pharmaceutics·2005
Same author

ANCOVA approach for shelf life analysis of stability study of multiple factor designs.

Journal of biopharmaceutical statistics·2003
Same author

Shelf life determination based on equivalence assessment.

Journal of biopharmaceutical statistics·2003
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study clarifies pharmaceutical stability designs like full, bracketing, and matrixing, emphasizing statistical considerations for accurate shelf-life estimation. It highlights potential issues with oversimplified designs to ensure regulatory compliance and product quality.

Area of Science:

  • Pharmaceutical Science
  • Statistics
  • Regulatory Affairs

Background:

  • Global pharmaceutical registration stability requirements have evolved significantly.
  • International Conference on Harmonization (ICH) guidelines address stability studies, but statistical design aspects require further clarification.
  • Accurate shelf-life estimation is critical for drug product quality and regulatory approval.

Purpose of the Study:

  • To exemplify and discuss statistical aspects of pharmaceutical stability designs (full, bracketing, matrixing) in relation to ICH guidelines.
  • To present statistical and regulatory considerations for selecting appropriate stability study designs.
  • To illustrate potential problems arising from overreduced designs using a case study.

Main Methods:

  • Exemplification of full, bracketing, and matrixing stability designs.

Related Experiment Videos

  • Statistical analysis and discussion of design choices.
  • Presentation of design comparison criteria and a case study.

    • Main Results:

    • Stability designs vary in their statistical efficiency and data requirements.
    • Overreduced designs can lead to inaccurate shelf-life estimations and regulatory non-compliance.
    • Careful selection of stability design is crucial for balancing statistical rigor and regulatory needs.

    Conclusions:

    • Well-designed stability studies are essential for precise drug product shelf-life determination.
    • Understanding the statistical implications of different designs (full, bracketing, matrixing) is vital for regulatory success.
    • Avoiding oversimplified designs prevents potential statistical and regulatory challenges.